This large, multicenter trial compared temsirolimus with interferon alfa alone and with a combination of the two drugs in patients with newly diagnosed metastatic renal-cell cancer and a poor prognosis. As compared with interferon alfa or combination therapy, temsirolimus was associated with a moderate improvement in survival among these high-risk patients.
More...